Abstract: A pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Abstract: The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Abstract: A capsulorhexis device is inserted into an incision site of a cornea to make an incision in an anterior capsule surrounding a crystalline lens. The capsulorhexis device includes a loop having elasticity and conductivity; a moving member having one end fixed and coupled to the loop; an insertion guide configured so that, while the incision is being made in the crystalline lens capsule, a front end thereof is inserted into the incision site of the cornea; and a housing having one end coupled to a rear end of the insertion guide, wherein the loop is housed in the housing and, to make the incision in the crystalline lens capsule, slides in the housing together with the moving member to pass through the insertion guide and be deployed into an anterior chamber of the eye.

Abstract: A capsulorhexis device is inserted into an incision site of a cornea to make an incision in an anterior capsule surrounding a crystalline lens. The capsulorhexis device includes a loop having elasticity and conductivity; a moving member having one end fixed and coupled to the loop; an insertion guide configured so that, while the incision is being made in the crystalline lens capsule, a front end thereof is inserted into the incision site of the cornea; and a housing having one end coupled to a rear end of the insertion guide, wherein the loop is housed in the housing and, to make the incision in the crystalline lens capsule, slides in the housing together with the moving member to pass through the insertion guide and be deployed into an anterior chamber of the eye.

Abstract: The present technology relates to a memory system and a method of operating the same. The memory system includes a memory device including a plurality of semiconductor memories, and a controller configured to control the memory device to select a victim block based on a fail bit number of some data, among data that is programmed in each of the plurality of semiconductor memories, corresponding to a specific program state, and configured to perform a garbage collection operation on the selected victim blocks.

Abstract: The present disclosure relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases including the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Abstract: The present technology relates to a memory system and a method of operating the same. The memory system includes a memory device including a plurality of semiconductor memories, and a controller configured to control the memory device to select a victim block based on a fail bit number of some data, among data that is programmed in each of the plurality of semiconductor memories, corresponding to a specific program state, and configured to perform a garbage collection operation on the selected victim blocks.

Abstract: A surgical apparatus for making an incision in a living tissue according to the present disclosure includes a hand piece including a loop-type electrode part and a generator configured to transmit electrical energy to the electrode part, wherein the generator applies electric-field pulse waveforms made of two consecutive pulse groups to the electrode part, the two consecutive pulse groups include a first pulse group and a second pulse group, each pulse group includes mini-pulses, a peak voltage of the first pulse group is less than a peak voltage of the second pulse group, and a duration of the first pulse group is longer than a duration of the second pulse group.

Abstract: The present invention relates to a pharmaceutical composition, an oral administration agent and an eye drop for preventing or treating retinal diseases or optic nerve diseases comprising the compound represented by the Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient and the pharmaceutical composition, the oral administration agent and the eye drop can effectively prevent or treat retinal disease or optic nerve disease.

Abstract: Provided herein is a capsulorhexis device (100) inserted into an incision site of a cornea to make an incision in an anterior capsule surrounding a crystalline lens. The capsulorhexis device includes a loop (110) having elasticity and conductivity, a moving member (120) having one end fixed and coupled to the loop (110), a head part (130) including a housing configured to store the loop (110) therein and an insertion guide (131) coupled to one end portion of the housing to communicate therewith, and a body (140) that is coupled to the other end portion of the housing and has a sliding button (141) provided to slide the loop (110) and the moving member (120) through the head part (130).

Abstract: Provided is a capsulorhexis apparatus for incising an anterior capsule covering a crystalline lens by being inserted into an incision site of a cornea, the capsulorhexis apparatus including: an anterior capsule incision portion which has a closed curve shape, is inserted into the incision site of the cornea to incise the anterior capsule located below the cornea to a circle, and generates heat by using high frequency vibration to incise the anterior capsule; a body portion which is externally exposed when the anterior capsule incision portion incises the anterior capsule while slidingly moving in the body portion, and is internally inserted when the anterior capsule incision portion does not incise the anterior capsule; and a button portion which is formed on one side of the body portion and slidingly moves the anterior capsule incision portion inside the body portion.

Abstract: A composition for preventing or treating dry eye syndrome includes nanocomposite of a polyethylene glycol and a flavonoid as an active ingredient, and in the present invention, a catechin/PEG nanocomposite having increased catechin bioavailability is prepared by using catechins which are an antioxidant and polyethylene glycol which is a hydrophilic polymer used in a drug delivery system, and an increase in tear generation, stabilization of corneal epithelial cells, an increase in conjunctival goblet cells and enhanced anti-inflammatory effects accordance to a PEG dosage by the catechin/PEG nanocomposite are confirmed in a mouse model with dry eye syndrome.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye.

Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.

Abstract: The present invention provides a capsulorhexis apparatus for incising the anterior capsule covering the crystalline lens by being inserted into an incision site of the cornea. The capsulorhexis apparatus comprises: an anterior capsule incision part which has a closed curve-shape, is inserted in an incision site of an incised cornea so as to incise one portion of the anterior capsule positioned at the lower part of the cornea, and generates heat by applying a current in order to incise the anterior capsule; a body part in which the anterior capsule incision part slidingly moves so that the anterior capsule incision part is exposed to the outside when same is incising one portion of the anterior capsule, and is inserted inside the body part when same is not incising the anterior capsule; and a button part which is formed on one surface of the body part and slidingly moves the anterior capsule incision part inside the body part.

Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.

Abstract: A composition for preventing or treating dry eye syndrome includes nanocomposite of a polyethylene glycol and a flavonoid as an active ingredient, and in the present invention, a catechin/PEG nanocomposite having increased catechin bioavailability is prepared by using catechins which are an antioxidant and polyethylene glycol which is a hydrophilic polymer used in a drug delivery system, and an increase in tear generation, stabilization of corneal epithelial cells, an increase in conjunctival goblet cells and enhanced anti-inflammatory effects accordance to a PEG dosage by the catechin/PEG nanocomposite are confirmed in a mouse model with dry eye syndrome.

Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.

Abstract: Disclosed is a novel peptide capable of preventing or treating ocular surface disease by inhibiting or improving pathological changes caused by neovascularization, opacification, fibrosis and inflammation of the cornea, the peptide having an amino acid sequence represented by SEQ ID NO: 1 and more particularly, provides a collagen type II ?1-based peptide isolated from an animal chondrocyte cell-derived extracellular matrix and use thereof.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating dry eye, the pharmaceutical composition including, as an active component, a novel peptide is disclosed, wherein it is confirmed that the peptide has effects on improving tear production and corneal surface smoothness for dry eyes induced by desiccation stress and suppressing detachment of corneal epithelial cells, reduction in conjunctival goblet cells, and generation of inflammatory factors, thereby applying a composition including the peptide as an active component to the pharmaceutical composition for preventing or treating dry eye.